Literature DB >> 17272986

Transplantation for amyloidosis.

Morie A Gertz1, Martha Q Lacy, Angela Dispenzieri, Suzanne R Hayman, Shaji Kumar.   

Abstract

PURPOSE OF REVIEW: High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin light-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature. RECENT
FINDINGS: We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial.
SUMMARY: Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17272986     DOI: 10.1097/CCO.0b013e32801494c6

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  15 in total

1.  Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.

Authors:  Vaishali Sanchorawala
Journal:  Am J Blood Res       Date:  2012-01-01

2.  Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.

Authors:  Vaishali Sanchorawala; Martha Skinner; Karen Quillen; Kathleen T Finn; Gheorghe Doros; David C Seldin
Journal:  Blood       Date:  2007-08-02       Impact factor: 22.113

3.  Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.

Authors:  Mark W Brunvand; Mitchell Bitter
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

4.  Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Authors:  Maria Teresa Cibeira; Vaishali Sanchorawala; David C Seldin; Karen Quillen; John L Berk; Laura M Dember; Adam Segal; Frederick Ruberg; Hans Meier-Ewert; Nancy T Andrea; J Mark Sloan; Kathleen T Finn; Gheorghe Doros; Joan Blade; Martha Skinner
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

Review 5.  Treatment of immunoglobulin light chain amyloidosis.

Authors:  Morie A Gertz; Steven R Zeldenrust
Journal:  Curr Hematol Malig Rep       Date:  2009-04       Impact factor: 3.952

6.  Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.

Authors:  Vaishali Sanchorawala; Jaymin M Patel; J Mark Sloan; Anthony C Shelton; Jerome B Zeldis; David C Seldin
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

7.  State-of-the-Art Management of Complications of Myeloma and Its Treatment.

Authors:  Monique A Hartley-Brown; Daniel M Sullivan; Rachid Baz
Journal:  Adv Hematol       Date:  2010-06-27

8.  Left ventricular ejection time on echocardiography predicts long-term mortality in light chain amyloidosis.

Authors:  Raymond Q Migrino; Ravi K Mareedu; Daniel Eastwood; Mark Bowers; Leanne Harmann; Parameswaran Hari
Journal:  J Am Soc Echocardiogr       Date:  2009-10-31       Impact factor: 5.251

9.  Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease.

Authors:  Saulius Girnius; David C Seldin; Martha Skinner; Kathleen T Finn; Karen Quillen; Gheorghe Doros; Vaishali Sanchorawala
Journal:  Haematologica       Date:  2009-05-19       Impact factor: 9.941

10.  CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy.

Authors:  Ping Zhou; Raymond L Comenzo; Adam B Olshen; Ezio Bonvini; Scott Koenig; Peter G Maslak; Martin Fleisher; James Hoffman; Suresh Jhanwar; James W Young; Stephen D Nimer; Adam M Boruchov
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.